thyrocalcitonin

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/28 20:06:16」(JST)

wiki en

[Wiki en表示]

Calcitonin-related polypeptide alpha
NMR solution structure of salmon calcitonin in SDS micelles.
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 1LS7, 2JXZ
Identifiers
Symbols	CALCA ; CALC1; CGRP; CGRP-I; CGRP1; CT; KC
External IDs	OMIM: 114130 MGI: 2151253 HomoloGene: 88401 ChEMBL: 5293 GeneCards: CALCA Gene
Gene ontology Molecular function • receptor binding • hormone activity • protein binding • calcitonin receptor binding • protein complex binding • identical protein binding Cellular component • extracellular region • extracellular space • nucleus • cytoplasm • neuronal cell body • terminal bouton Biological process • endothelial cell proliferation • vasculature development • neurological system process involved in regulation of systemic arterial blood pressure • vasodilation of artery involved in baroreceptor response to increased systemic arterial blood pressure • regulation of heart rate • G-protein coupled receptor internalization • monocyte chemotaxis • protein phosphorylation • inflammatory response • leukocyte cell-cell adhesion • adenylate cyclase-activating G-protein coupled receptor signaling pathway • activation of adenylate cyclase activity • positive regulation of cytosolic calcium ion concentration • neuropeptide signaling pathway • cell-cell signaling • embryo implantation • aging • feeding behavior • regulation of blood pressure • response to heat • negative regulation of calcium ion transport into cytosol • negative regulation of ossification • positive regulation of cAMP biosynthetic process • receptor internalization • negative regulation of neurological system process • activation of protein kinase activity • positive regulation of interleukin-1 alpha production • positive regulation of interleukin-8 production • endothelial cell migration • positive regulation of macrophage differentiation • negative regulation of osteoclast differentiation • positive regulation of adenylate cyclase activity • negative regulation of blood pressure • positive regulation of ossification • negative regulation of bone resorption • negative regulation of transcription, DNA-templated • positive regulation of vasodilation • negative regulation of smooth muscle contraction • response to pain • regulation of inflammatory response • detection of temperature stimulus involved in sensory perception of pain • cytosolic calcium ion homeostasis • positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	796	12310
Ensembl	ENSG00000110680	ENSMUSG00000030669
UniProt	P01258	P70160
RefSeq (mRNA)	NM_001033952	NM_001033954
RefSeq (protein)	NP_001029124	NP_001029126
Location (UCSC)	Chr 11: 14.99 – 14.99 Mb	Chr 7: 114.63 – 114.64 Mb
PubMed search	[1]	[2]

Calcitonin (also known as thyrocalcitonin) is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body. It acts to reduce blood calcium (Ca²⁺), opposing the effects of parathyroid hormone (PTH).

Calcitonin has been found in fish, reptiles, birds, and mammals. Its importance in humans has not been as well established as its importance in other animals, as its function is usually not significant in the regulation of normal calcium homeostasis. It belongs to the calcitonin-like protein family.

Biosynthesis and regulation

Calcitonin is formed by the proteolytic cleavage of a larger prepropeptide, which is the product of the CALC1 gene (CALCA). The CALC1 gene belongs to a superfamily of related protein hormone precursors including islet amyloid precursor protein, calcitonin gene-related peptide, and the precursor of adrenomedullin.

Secretion of calcitonin is stimulated by:

• an increase in serum [Ca²⁺]
• gastrin and pentagastrin.

Effects

The hormone participates in calcium (Ca²⁺) and phosphorus metabolism. In many ways, calcitonin counteracts parathyroid hormone (PTH).

More specifically, calcitonin lowers blood Ca²⁺ levels in four ways:

• Inhibits Ca²⁺ absorption by the intestines
• Inhibits osteoclast activity in bones
• Stimulates osteoblastic activity in bones.
• Inhibits renal tubular cell reabsorption of Ca²⁺ allowing it to be excreted in the urine

However, effects of calcitonin that mirror those of PTH include the following:

• Inhibits phosphate reabsorption by the kidney tubules

In its skeleton-preserving actions, calcitonin protects against calcium loss from skeleton during periods of calcium mobilization, such as pregnancy and, especially, lactation.

Other effects are in preventing postprandial hypercalcemia resulting from absorption of Ca²⁺. Also, calcitonin inhibits food intake in rats and monkeys, and may have CNS action involving the regulation of feeding and appetite.

Receptor

The calcitonin receptor, found on osteoclasts, and in kidney and regions of the brain, is a G protein-coupled receptor, which is coupled by G_s to adenylate cyclase and thereby to the generation of cAMP in target cells. It may also affect the ovaries in women and the testes in men.

Discovery

Calcitonin was purified in 1962 by Copp and Cheney. While it was initially considered a secretion of the parathyroid glands, it was later identified as the secretion of the C-cells of the thyroid gland.

Pharmacology

Salmon calcitonin is used for the treatment of:

• Postmenopausal osteoporosis
• Hypercalcaemia
• Paget's disease
• Bone metastases
• Phantom limb pain

It has been investigated as a possible non-operative treatment for spinal stenosis.

The following information is from the UK Electronic Medicines Compendium

General characteristics of the active substance

Salmon calcitonin is rapidly absorbed and eliminated. Peak plasma concentrations are attained within the first hour of administration.

Animal studies have shown that calcitonin is primarily metabolised via proteolysis in the kidney following parenteral administration. The metabolites lack the specific biological activity of calcitonin. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively).

Calcitonin has short absorption and elimination half-lives of 10–15 minutes and 50–80 minutes, respectively. Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. Therefore, the metabolic clearance is much lower in patients with end-stage renal failure than in healthy subjects. However, the clinical relevance of this finding is not known. Plasma protein binding is 30% to 40%.

Characteristics in patients

There is a relationship between the subcutaneous dose of calcitonin and peak plasma concentrations. Following parenteral administration of 100 IU calcitonin, peak plasma concentration lies between about 200 and 400 pg/ml. Higher blood levels may be associated with increased incidence of nausea, vomiting, and secretory diarrhea.

Preclinical safety data

Conventional long-term toxicity, reproduction, mutagenicity, and carcinogenicity studies have been performed in laboratory animals. Salmon calcitonin is devoid of embryotoxic, teratogenic, and mutagenic potential.

An increased incidence of pituitary adenomas has been reported in rats given synthetic salmon calcitonin for 1 year. This is considered a species-specific effect and of no clinical relevance. Salmon calcitonin does not cross the placental barrier.

In lactating animals given calcitonin, suppression of milk production has been observed. Calcitonin is secreted into the milk.

Pharmaceutical manufacture

Calcitonin was extracted from the ultimobranchial glands (thyroid-like glands) of fish, particularly salmon. Salmon calcitonin resembles human calcitonin, but is more active. At present, it is produced either by recombinant DNA technology or by chemical peptide synthesis. The pharmacological properties of the synthetic and recombinant peptides have been demonstrated to be qualitatively and quantitatively equivalent.

Uses of calcitonin

Treatments

Calcitonin can be used therapeutically for the treatment of hypercalcemia or osteoporosis.

Oral calcitonin may have a chondroprotective role in osteoarthritis (OA), according to data in rats presented in December, 2005, at the 10th World Congress of the Osteoarthritis Research Society International (OARSI) in Boston, Massachusetts. Although calcitonin is a known antiresorptive agent, its disease-modifying effects on chondrocytes and cartilage metabolisms have not been well established until now.

This new study, however, may help to explain how calcitonin affects osteoarthritis. “Calcitonin acts both directly on osteoclasts, resulting in inhibition of bone resorption and following attenuation of subchondral bone turnover, and directly on chondrocytes, attenuating cartilage degradation and stimulating cartilage formation,” says researcher Morten Karsdal, MSC, PhD, of the department of pharmacology at Nordic Bioscience in Herlev, Denmark. “Therefore, calcitonin may be a future efficacious drug for OA.”

Subcutaneous injections of calcitonin in patients suffering from mania resulted in significant decreases in irritability, euphoria and hyperactivity and hence calcitonin holds promise for treating bipolar disorder. However no further work on this potential application of calcitonin has been reported.

Diagnostics

It may be used diagnostically as a tumor marker for medullary thyroid cancer, in which high calcitonin levels may be present and elevated levels after surgery may indicate recurrence. It may even be used on biopsy samples from suspicious lesions (e.g., lymph nodes that are swollen) to establish whether they are metastasis of the original cancer.

Cutoffs for calcitonin to distinguish cases with medullary thyroid cancer have been suggested to be as follows, with a higher value increasing the suspicion of medullary thyroid cancer:

• females: 5 ng/L or pg/mL
• males: 12 ng/L or pg/mL
• children under 6 months of age: 40 ng/L or pg/mL
• children between 6 months and 3 years of age: 15 ng/L or pg/mL

When over 3 years of age, adult cutoffs may be used

Increased levels of calcitonin have also been reported for various other conditions. They include: C-cell hyperplasia, Nonthyroidal oat cell carcinoma, Nonthyroidal small cell carcinoma and other nonthyroidal malignancies, acute and chronic renal failure, hypercalcemia, hypergastrinemia and other gastrointestinal disorders, and pulmonary disease.

Structure

Calcitonin is a polypeptide hormone of 32 amino acids, with a molecular weight of 3454.93 daltons. Its structure comprises a single alpha helix. Alternative splicing of the gene coding for calcitonin produces a distantly related peptide of 37 amino acids, called calcitonin gene-related peptide (CGRP), beta type.

The following are the amino acid sequences of salmon and human calcitonin:

• salmon:

      Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

• human:

      Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro

Compared to salmon calcitonin, human calcitonin differs at 16 residues.

See also

• Procalcitonin

References

Further reading

• MacIntyre I, Alevizaki M, Bevis PJ, Zaidi M (1987). "Calcitonin and the peptides from the calcitonin gene". Clin. Orthop. Relat. Res. &na; (217): 45–55. doi:10.1097/00003086-198704000-00007. PMID 3549095. 
• Di Angelantonio S, Giniatullin R, Costa V et al. (2004). "Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells". Br. J. Pharmacol. 139 (6): 1061–73. doi:10.1038/sj.bjp.0705337. PMC 1573932. PMID 12871824. 
• Findlay DM, Sexton PM (2005). "Calcitonin". Growth Factors 22 (4): 217–24. doi:10.1080/08977190410001728033. PMID 15621724. 
• Sponholz C, Sakr Y, Reinhart K, Brunkhorst F (2007). "Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature". Critical care (London, England) 10 (5): R145. doi:10.1186/cc5067. PMC 1751067. PMID 17038199. 
• Schneider HG, Lam QT (2007). "Procalcitonin for the clinical laboratory: a review". Pathology 39 (4): 383–90. doi:10.1080/00313020701444564. PMID 17676478. 
• Grani, G; Nesca, A; Del Sordo, M; Calvanese, A; Carbotta, G; Bianchini, M; Fumarola, A (Jun 2012). "Interpretation of serum calcitonin in patients with chronic autoimmune thyroiditis.". Endocrine-related cancer (Bioscientifica) 19 (3): 345–9. doi:10.1530/ERC-12-0013. PMID 22399011. 

External links

• The Calcitonin Protein
• Calcitonin at the US National Library of Medicine Medical Subject Headings (MeSH)

English Journal

• Headache after exposure to 'date-rape' drugs.

• Peatfield R, Villalón CM.SourcePrincess Margaret Migraine Clinic, Charing Cross Hospital, London, W6 8RF UK.
• SpringerPlus.Springerplus.2013 Dec;2(1):39. Epub 2013 Feb 8.
• SUMMARY: We report two patients who developed a prolonged featureless headache, they think after a drink was 'spiked'. We speculate that each was exposed to scopolamine, resulting in enhanced trigeminal release of vasodilator neuropeptides, including Calcitonin Gene-Related Peptide (CGRP), and thus
• PMID 23451337

• Effect of Fluoride and Low versus High Levels of Dietary Calcium on mRNA Expression of Osteoprotegerin and Osteoprotegerin Ligand in the Bone of Rats.

• Yu J, Gao Y, Sun D.SourceCenter for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China.
• Biological trace element research.Biol Trace Elem Res.2013 Jun;152(3):387-95. doi: 10.1007/s12011-013-9633-8. Epub 2013 Mar 3.
• The ratio of osteoprotegerin ligand (OPGL) to osteoprotegerin (OPG) determines the delicate balance between bone resorption and synthesis. The main objective of the present study is to investigate the possible role of OPGL and OPG in the bone metabolism of rats exposed to fluoride and the protective
• PMID 23456427

Japanese Journal

• Decrease in thyrocalcitonin-containing cells and analysis of other congenital anomalies in 11 patients with DiGeorge anomaly

• Am J Med Genet 46, 641-646, 1993
• NAID 30001972522

• 多数歯埋伏を伴った大理石骨病の１例

• 日本口腔外科学会雑誌 34(9), 1987-1993, 1988
• NAID 130001357063

• 高Ｃａ血症をきたした造血器腫ようの検討

• 臨床血液 27(11), 2070-2077, 1986
• NAID 130004498916

Related Links

• Definition of Thyrocalcitonin - MedTerms

Online Medical Dictionary and glossary with medical definitions.

Related Pictures

---

★リンクテーブル★

リンク元	「カルシトニン」「サイロカルシトニン」

「カルシトニン」

　　[★]

英

calcitonin (Z,PT), CT

同

サイロカルシトニン thyrocalcitonin

関

パラソルモン、甲状腺、副甲状腺。プロカルシトニン

• 「血中カルシウム濃度が高くすぎないように調節する」ホルモン

性状

• ペプチド(32aa)

産生組織

• 甲状腺の傍濾胞細胞(C細胞)　→　サイロカルシトニン
• 胸腺、視床下部、下垂体　→　カルシトニン

標的組織

• 骨
• 腎臓

作用 (2007年度後期生理学授業プリント)

• 血中カルシウム濃度↓ (血中カルシウム濃度が高いときのみ)
• 破骨細胞に作用して骨吸収を抑制
• 尿細管に作用してCa,P,Na,Clを排泄
• 腸管に作用してカルシウムの吸収を抑制する
• 胃酸分泌を下げる

分泌の調節 (2007年度後期生理学授業プリント)

• 血中のカルシウム濃度(カルシウムイオン、タンパク質に結合しているカルシウムを含む)が高いときにサイロカルシトニンが分泌される。
• 血中カルシウム濃度　5mEq/l　このうち血中カルシウムイオン濃度は 2.5 mEq/l

分泌調節のポイント：カルシトニン ←Ca²⁺ + protein binding Ca　。　副甲状腺ホルモン　←Ca²⁺

「サイロカルシトニン」

　　[★]

英

thyrocalcitonin, TCT

関

カルシトニン

• カルシトニンのうち、特に甲状腺の濾胞上皮細胞で産生・分泌されるものを指す (2007年度後期生理学授業プリント)